Oncology Institute (NASDAQ:STLN) Stock Price Target Raised at BTIG Research

Posted by Stanley Muller on Nov 7th, 2026

Oncology Institute (NASDAQ:STLN – Free Report) had its target price hoisted by BTIG Research from $9.00 to $10.00 in a report issued on Friday morning,Benzinga reports. BTIG Research currently has a buy rating on the stock.

A number of other equities analysts have also recently issued reports on STLN. Needham & Company LLC increased their price objective on shares of Oncology Institute from $7.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, October 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oncology Institute in a research note on Tuesday. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $9.75.

Get Our Latest Analysis on STLN

Oncology Institute Trading Down 46.0%

Shares of NASDAQ:STLN traded down $3.08 during trading on Friday, reaching $3.62. The stock had a trading volume of 23,895,218 shares, compared to its average volume of 1,268,476. The stock has a market capitalization of $357.80 million, a PE ratio of -12.48 and a beta of 0.44. The business’s fifty day moving average is $6.43. Oncology Institute has a 52 week low of $2.32 and a 52 week high of $7.13.

Oncology Institute (NASDAQ:STLN – Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The firm had revenue of $169.77 million during the quarter. As a group, research analysts predict that Oncology Institute will post -0.21 earnings per share for the current year.

Insider Buying and Selling at Oncology Institute

In related news, Director Brad Hively sold 298,853 shares of the business’s stock in a transaction on Friday, August 21st. The stock was sold at an average price of $6.51, for a total transaction of $1,945,533.03. Following the sale, the director directly owned 411,976 shares in the company, valued at approximately $2,681,963.76. The trade was a 42.04% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Jorey Chernett bought 12,000 shares of the stock in a transaction dated Friday, August 14th. The stock was bought at an average cost of $6.54 per share, with a total value of $78,480.00. Following the purchase, the insider owned 10,660,858 shares in the company, valued at $69,722,011.32. The trade was a 0.11% increase in their position. The SEC filing for this purchase provides additional information. Corporate insiders own 4.40% of the company’s stock.

Institutional Trading of Oncology Institute

Institutional investors have recently bought and sold shares of the company. BlackRock Inc. bought a new position in shares of Oncology Institute in the second quarter worth approximately $25,787,000. State Street Corp bought a new position in Oncology Institute in the 2nd quarter valued at approximately $8,432,000. Renaissance Technologies LLC boosted its stake in Oncology Institute by 25.1% during the 1st quarter. Renaissance Technologies LLC now owns 902,809 shares of the company’s stock valued at $2,772,000 after purchasing an additional 180,909 shares during the last quarter. FourWorld Capital Management LLC boosted its stake in Oncology Institute by 30.4% during the 1st quarter. FourWorld Capital Management LLC now owns 499,196 shares of the company’s stock valued at $1,533,000 after purchasing an additional 116,496 shares during the last quarter. Finally, Manatuck Hill Partners LLC bought a new stake in shares of Oncology Institute in the 2nd quarter worth $2,444,000. 36.86% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Oncology Institute

Here are the key news stories impacting Oncology Institute this week:

Positive Sentiment: BTIG Research raised its price target to $10 from $9 and maintained a “buy” rating, indicating substantial potential upside in its view. TickerReport article
Neutral Sentiment: B. Riley reaffirmed its “buy” rating but lowered its target to $10 from $11, signaling continued optimism alongside a more cautious valuation. B. Riley rating
Negative Sentiment: For the third quarter, the company reported a loss of $0.13 per share, worse than the $0.07 loss analysts expected, although the loss narrowed from $0.14 a year earlier. Revenue was $169.77 million and beat estimates. Quarterly results coverage
Negative Sentiment: Full-year 2026 revenue guidance of $650 million–$660 million came in below the $665 million consensus estimate, raising concern about the company’s growth outlook. Company results and guidance

About Oncology Institute

(Get Free Report)

The Oncology Institute is a value-based oncology care company focused on delivering comprehensive cancer treatment and related services through community-based care settings. Its model is designed to support patients throughout the cancer-care journey while coordinating treatment among oncologists, primary-care providers, specialists and other healthcare professionals.

The company provides medical oncology and hematology services, cancer screening and diagnosis, treatment planning, chemotherapy and other infusion therapies, supportive care, survivorship services and care-management programs.